Moderna says it has become the first company in the pharma sector with phase 3 data on a combined vaccine for both COVID-19 and influenza and will soon be ready to discuss “next steps” with regulatory authorities.
The trial of mRNA-1083 met its objectives, stimulating higher immune responses against influenza and SARS-CoV-2 than the licensed flu and COVID vaccines used as comparators in the trial, which involved adults 50 years and older.
